InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: None

Friday, 05/09/2014 3:47:14 PM

Friday, May 09, 2014 3:47:14 PM

Post# of 426269
Assumptions / facts:
- R-IT SPA will not modified, so interim analysis will be done at 967 events.
- Vascepa efficacy is at least 25%, so 967 would happen in March 2016 as earliest with results expected to be available by end of 2016
- they will close 2014 around 115M cash ("We continue to estimate that during 2014, our net cash outflows will be less than $80 million", they already "used" 27,5M, so less than 52,5M during Q2-Q4 2014)
- w same cash burn it will be enough till end of Q2 2016

Conclusion: they need additional 40-60M till end of 2016 and it's not impossible.

and it's w/o Anchhor.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News